Kent Lake Capital’s Myriad Genetics MYGN Stock Holding History

Kent Lake Capital’s Portfolio MYGN Stock Details MYGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-108,377	Closed	-$2.07M	–	56
2023 Q4	$2.07M	Buy	+108,377	New	+$1.87M	0.8%	38

Other funds holding MYGN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

CCM

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

GCM

Glenview Capital Management New York $3.98B AUM 20.52% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Kent Lake Capital's MYGN Position: Q1 2024 in Review

Kent Lake Capital sold out of Myriad Genetics (MYGN) in Q1 2024, closing a stake of 108,377 shares — an estimated $2.07M sold.

Kent Lake Capital first reported a position in MYGN in Q4 2023 and held it in 1 quarter. The position peaked at $2.07M in Q4 2023. 186 funds tracked by Wall St. Rank hold MYGN as of Q1 2024.

Kent Lake Capital reported no remaining Myriad Genetics position as of Q1 2024 after selling out during the quarter.
Kent Lake Capital sold 108,377 Myriad Genetics shares in Q1 2024, an estimated $2.07M.
Kent Lake Capital first reported a position in Myriad Genetics in Q4 2023 and held it in 1 quarter.
Kent Lake Capital's Myriad Genetics position peaked at $2.07M in Q4 2023.
186 funds tracked by Wall St. Rank held Myriad Genetics as of Q1 2024.

Based on Kent Lake Capital's 13F filing for Q1 2024, filed 15 May 2024.